Paclitaxel USP

Composition: Ontaxel-30 IV Injection: Each vial contains 16.7ml solution containing Paclitaxel USP 30 mg (6 mg/ml).

Packing: Ontaxel 30 injection: Each box contains 1 vial (16.7ml) Paclitaxel.

Dosage & Administration: Ovarian Cancer First line treatment in combination with cisplatin : Ontaxel administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2 every 3 weeks Ontaxel administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2 every 3 weeks In patients previously treated with chemotherapy for carcinoma of the ovary, Ontaxel has been use at several doses and schedules; however,the optimal regimem is not yet clear.The recommended regimen is Ontaxel (paclitaxel) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks. Breast Cancer : - 175 mg/m2 administered IV over 3 hours every 3 weeks has been shown to be effective after failure of chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. AIDS-related Kaposi's sarcoma : - 135 mg/m2 given IV over 3 hours every 3 weeks or at a dose of 100 mg/m2 given IV. over 3 hours every 2 weeks is recommended (dose intensity 45-50 mg/ m2 /week) Lung cancer : - For the first-line treatment of NSCLC, in combination with cisplatin, in patients who are not candidates for potentially curative surgery and/or radiation therapy. -135 mg/m2 IV administered over 24 hours followed by cisplatin. The regimen to be repeated every 3 weeks based on the clinical status of the patient. Gastric Cancer : - Once daily 210 mg/m2 (Body surface area) by 3 hours intravenous infusion for adults. At least 3 week of dosing interval is of absolute necessity. Dosage modification for toxicity (solid tumors, including ovary, breast, and lung carcinoma) : Courses of Paclitaxel should not be repeated until the neutrophil count is> 1500 cells/mm3 and the platelet count is> 100,000 cells/mm3; reduce dosage by 20% for patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil <500>

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2021 Designed and Developed by ATI Limited.